المؤلفون: О. Неханевич, О. Смирнова, В. Васильченко, Р. Лосєва

المصدر: Неонатологія, хірургія та перинатальна медицина, Vol 14, Iss 2(52) (2024)

مصطلحات موضوعية: травма спинного мозку, реабілітація, прогнозування, органи тазу, сечовий міхур, кишківник, якість життя., Pediatrics, RJ1-570, Gynecology and obstetrics, RG1-991

وصف الملف: electronic resource

Relation: http://neonatology.bsmu.edu.ua/article/view/307734; https://doaj.org/toc/2226-1230; https://doaj.org/toc/2413-4260

URL الوصول: https://doaj.org/article/eca86996fa3f404998da5ad4e9b55864

المؤلفون: Y. Wang, L. F. Mufazalova, N. A. Mufazalova, V. I. Korunas, N. V. Ilyasova, A. V. Vasilchenko, A. V. Samorodov, Юи Ванг, Л. Ф. Муфазалова, Н. А. Муфазалова, В. И. Корунас, Н. В. Ильясова, А. В. Васильченко, А. В. Самородов

المصدر: Creative surgery and oncology; Том 13, № 4 (2023); 330-334 ; Креативная хирургия и онкология; Том 13, № 4 (2023); 330-334 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: бриварацетам, antiepileptic drugs, epilepsy, malignant neoplasms of the brain, efficacy, levetiracetam, brivaracetam, противоэпилептические препараты, эпилепсия, злокачественные новообразования головного мозга, эффективность, леветирацетам

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/857/569; https://www.surgonco.ru/jour/article/view/857/583; Odintsova G.V., Abramov K.B., Ivanova N.E., Samochernykh K.A., Khachatryan V.A., Konradi A.O., et al. “Epilepsy 90–80–70”: Intersectoral global Action Plan on epilepsy and other neurological disorders (2022–2031). Translational medicine. 2023;10(4):285–92 (In Russ.). DOI:10.18705/2311-4495-2023-10-4-285-292; Khaibullina R.R., Danilko K.V., Valeeva G.A., Shangina O.R. A method to treat periodontitis using a stromal-vascular fraction of human adipose tissue and an osteogenesis stimulator drug: Russian Federation patent 2800646 C1 2023 July 25 (In Russ.).; Khaibullina R.R., Danilko K.V., Lopatina N.V., Shangina O.R. A method to treat gum recession using gingival tissue and a regenerative stimulator drug: Russian Federation patent 2803692 C1 2023 Sept 19 (In Russ.).; Goldstein E.D., Feyissa A.M. Brain tumor related-epilepsy. Neurol Neurochir Pol. 2018;52(4):436–47. DOI:10.1016/j.pjnns.2018.06.001; Kwan P., Trinka E., Van Paesschen W., Rektor I., Johnson M, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55:38–46. DOI:10.1111/epi.12391; Nedbayeva D.N., Sirotkina O.V., Mineeva E.V., Vasilyeva E.Yu., Morozova E.I., Vavilova T.V., et al. The effect of comorbid pathology on the indicators of platelet functional activity in patients with unstable angina. Translational medicine. 2023;10(4):252–63 (In Russ.). DOI:10.18705/2311-4495-2023-10-4-252-263; Armstrong T.S., Grant R., Gilbert M.R., Lee J.W., Norden A.D. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy. Neuro-Oncol. 2016;18(6):779–89. DOI:10.1093/neuonc/nov269; Weller M., Stupp R., Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13(9):e375–82. DOI:10.1016/S1470-2045(12)70266-8; Nazaralieva E.T., Fedorov V.S., Zabrodskaya Y.M., Kim A.V., Dzhanaliev B.R., Shevtsov M.A., et al. Heat shock proteins as diagnostic and prognostic markers in malignant tumors of the central nervous system. Translational Medicine. 2022;9(6):5–15 (In Russ.). DOI:10.18705/2311-4495-2022-9-6-5-15; Odintsova G.V., Ermolaeva V.D., Samochernykh K.A., Ivanova N.E., Dengina N.O. Screening study of comorbid affective disorders in patients with pharmacoresistant epilepsy in a neurosurgical hospital. Translational Medicine. 2022;9(6):36–43 (In Russ.). DOI:10.18705/2311-4495-2022-9-6-36-43; Slegers R.J., Blumcke I. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. Acta Neuropathol Commun. 2020;8(1):27. DOI:10.1186/s40478-020-00904-x; Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10:124–33. DOI:10.2174/157015912800604470; Borshevetskaya A.A., Trushina L.I., Efimtsev A.Yu., Ternovyh I.K., Galyautdinova L.E., Egorova V.S., et al. Methods of radiation diagnosis of sleep disorders in patients with acute ischemic stroke. Translational Medicine. 2022;9(6):44–58 (In Russ.). DOI:10.18705/23114495-2022-9-6-44-58; Petrishchev N.N., Shlyakhto E.V., Tsyrlin V.A. The role of oxygen free radicals in the mechanisms of local and distant ischemic preconditioning of the myocardium. Annals of the Russian Academy of Medical Sciences. 2006;8:10–5 (In Russ.).; Maschio M., Dinapoli L., Zarabla A., Jandolo B. Issues related to the pharmacological management of patients with brain tumours and epilepsy. Funct Neurol. 2006;21(1):15–9. PMID: 16734997.; Pazgan-Simon M., Simon K.A., Jarowicz E., Rotter K., Szymanek-Pasternak A., Zuwała-Jagiełło J. Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence. Clin Exp Hepatol. 2018;4(3):210–6. DOI:10.5114/ceh.2018.78127; Bautin A.E., Galagudza M.M., Datsenko S.V., Tashkhanov D.M., Marichev A.O., Bakanov A.Yu., et al. The effect of distant ischemic preconditioning on the course of the perioperative period with isolated prosthetics of the aortic valve. The Russian journal of Anesthesiology and Reanimatology. 2014;3:11–7 (In Russ.).; Shlyakhto E.V., Barantsevich E.R., Shcherbak N.S., Galagudza M.M. Molecular mechanisms to form ischemic tolerance of the brain. Part 1. Annals of the Russian Academy of Medical Sciences. 2012;67(6):42–50 (In Russ.). DOI:10.15690/vramn.v67i6.283; Brandt C., Klein P., Badalamenti V., Gasalla T., Whitesides J. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. Epilepsy Behav. 2020;103(Pt A):106864. DOI:10.1016/j.yebeh.2019.106864; Maschio M., Maialetti A., Mocellini C., Domina E., Pauletto G., Costa C., et al. Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study. Front Neurol. 2020;11:813. DOI:10.3389/fneur.2020.00813; Klein P., Schiemann J., Sperling M., Whitesides J., Liang W., Stalvey T. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890–8. DOI:10.1111/epi.13212; Pace A., Dirven L., Koekkoek J.A.F., Golla H., Fleming J., Rudà R., et al. European Association of Neuro-Oncology palliative care task force. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017;18(6):e330–40. DOI:10.1016/S1470-2045(17)30345-5; Marku M., Rasmussen B.K., Belmonte F., Andersen E.A.W., Johansen C., Bidstrup P.E. Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018. J Neurooncol. 2022;157(1):71–80. DOI:10.1007/s11060-022-03948-2; Liang S., Fan X., Zhao M., Shan X., Li W., Ding P., et al Clinical practice guidelines for the diagnosis and treatment of adult diffuse gliomarelated epilepsy. Cancer Med. 2019;8(10):4527–35. DOI:10.1002/cam4.2362; Englot D.J., Chang E.F., Vecht C.J. Epilepsy and brain tumors. Handb Clin Neurol. 2016;134:267–85. DOI:10.1016/B978-0-12-802997-8.00016-5; Samudra N., Zacharias T., Plitt A., Lega B., Pan E. Seizures in glioma patients: An overview of incidence, etiology, and therapies. J Neurol Sci. 2019;404:80–5. DOI:10.1016/j.jns.2019.07.026; Zhou C., Fang S., Yang J., Wang Y., Wang L. Epilepsy-related white matter network changes in patients with frontal lobe glioma. J Neuroradiol. 2023;50(2):258–65. DOI:10.1016/j.neurad.2022.03.007; Izumoto S., Miyauchi M., Tasaki T., Okuda T., Nakagawa N., Nakano N., et al. Seizures and tumor progression in glioma patients with uncontrollable epilepsy treated with perampanel. Anticancer Res. 2018;38(7):4361–6. DOI:10.21873/anticanres.12737; He X., Zhang K., Liu D., Yang Z., Li X., Yang Z. Predictors of seizure outcomes in patients with diffuse low-grade glioma-related epilepsy after complete glioma removal. CNS Neurosci Ther. 2023;29(2):736–43. DOI:10.1111/cns.14061; Wasilewski A., Serventi J., Ibegbu C., Wychowski T., Burke J., Mohile N. Epilepsy education in gliomas: engaging patients and caregivers to improve care. Support Care Cancer. 2020;28(3):1405–9. DOI:10.1007/s00520-019-04968-x; https://www.surgonco.ru/jour/article/view/857

الاتاحة: https://www.surgonco.ru/jour/article/view/857
https://doi.org/10.24060/2076-3093-2023-13-4-5

المؤلفون: A. S. Safonov, M. V. Zabelin, A. A. Izmailov, Z. A. Valiullina, A. R. Mukhametkulova, A. V. Vasilchenko, K. N. Zolotukhin, А. С. Сафонов, М. В. Забелин, А. А. Измайлов, З. А. Валиуллина, А. Р. Мухаметкулова, А. В. Васильченко, К. Н. Золотухин

المساهمون: This work is not funded, Данная работа не финансировалась

المصدر: Creative surgery and oncology; Том 13, № 2 (2023); 165-170 ; Креативная хирургия и онкология; Том 13, № 2 (2023); 165-170 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: факторы риска, hemostatic system, P-selectin expression, renal replacement therapy, hemodialysis, renal failure, risk factors, система гемостаза, экспрессия Р-селектина, почечно-заместительная терапия, гемодиализ, почечная недостаточность

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/814/551; Global Burden of Disease Study Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392 (10159): 1736–88. DOI:10.1016/S0140-6736(18)32203-7; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–22. DOI:10.1016/S0140-6736(20)30925-9; Santucci C., Carioli G., Bertuccio P., Malvezzi M., Pastorino U., Boffetta P., et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev. 2020;29 (5): 367–81. DOI:10.1097/CEJ.0000000000000594; Xie X., Li F., Xie L., Yu Y., Ou S., He R. Meta-analysis of cancer risk among end stage renal disease undergoing maintenance dialysis. Open Life Sci. 2023; 18 (1): 20220553. DOI:10.1515/biol-2022-0553; Miyamoto Y., Iwagami M., Aso S., Uda K., Fushimi K., Hamasaki Y., et al. Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: a matched-pair cohort study. Clin Kidney J. 2022; 15 (6): 1137–43. DOI:10.1093/ckj/sfac005; Wong G., Staplin N., Emberson J., Baigent C., Turner R., Chalmers J., et al. Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies. BMC Cancer. 2016;16:488. DOI:10.1186/s12885-016-2532-6; Хайбуллина Р. Р., Данилко К. В., Шангина О. Р., Валеева Г. А., Лопатина Н. В., Герасимова Л. П. Способ лечения пародонтита с помощью мультипотентных мезенхимальных стволовых клеток пульпы зуба человека и препарата стимулятора остеогенеза : патент Российской Федерации № 2785009 от 01. 12. 2022.; Хайбуллина Р. Р., Данилко К. В., Шангина О. Р., Валеева Г. А., Лопатина Н. В., Галиахметова И. А., Герасимова Л. П., Кабирова М. Ф. Способ лечения пародонтита с использованием смеси микса мягких и твердых частиц элитных семян крамбе сорта санмо и фитоконцентрата санмо : патент Российской Федерации № 2785008 от 01. 12. 2022.; Хайбуллина Р. Р., Данилко К. В., Шангина О. Р., Лопатина Н. В., Валеева Г. А., Галиахметова И. А., Герасимова Л. П., Кабирова М. Ф. Способ лечения рецессии десны с использованием мультипотентных мезенхимальных стволовых клеток : патент Российской Федерации № 2785189 от 05. 12. 2022.; Хайбуллина Р. Р., Данилко К. В., Лопатина Н. В., Галиахметова И. А., Герасимова Л. П., Кабирова М. Ф. Способ лечения рецессии десны с использованием масла SANS MOTS : патент Российской Федерации № 2787679 от 11. 01. 2023.; Хайбуллина Р. Р., Данилко К. В., Лопатина Н. В., Герасимова Л. П. Способ моделирования рецессии десны : патент Российской Федераци № 2791563 от 10. 03. 2023.; Jorgensen L., Heuch I., Jenssen T., Jacobsen B. K. Association of albuminuria and cancer incidence. J Am Soc Nephrol. 2008; 19 (5): 992–8. DOI:10.1681/ASN.2007060712; Habas E., Akbar R., Farfar K., Arrayes N., Habas A., Rayani A., et al. Malignancy diseases and kidneys: A nephrologist prospect and updated review. Medicine (Baltimore). 2023; 102 (15): e33505. DOI:10.1097/MD.0000000000033505; Lowrance W. T., Ordonez J., Udaltsova N., Russo P., Go A. S. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014; 25 (10): 2327–34. DOI:10.1681/ASN.2013060604; Chinnadurai R., Flanagan E., Jayson G. C., Kalra P. A. Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study. BMC Nephrol. 2019; 20 (1): 380. DOI:10.1186/s12882-019-1578-5; Swier N., Versteeg H. H. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression. Th rombosis Research. 2017; 150: 8–18. DOI:10.1016/j.thromres.2016.12.002; Brandenburger T., Dimski T., Slowinski T., Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017; 31 (3): 387–401. DOI:10.1016/j.bpa.2017.08.005; Fisher R., Moore G. W., Mitchell M. J., Dai L., Crichton S., Lumlertgul N., et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann Intensive Care. 2022; 12 (1): 29. DOI:10.1186/s13613-022-01004-w; Wang Z. Y., Feng S. H., Fan B. L., Ma W., Jia X. C., Geng H. Effects of regional citrate anticoagulation in continuous veno-venous hemofi ltration of severe burn patients. Zhonghua Shao Shang Za Zhi. 2021; 37 (12): 1137–42. Chinese. DOI:10.3760/cma.j.cn501120-20200816-00381; Zhang C., Lin T., Zhang J., Liang H., Di Y., Li N., et al. Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury aft er hepatectomy. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018; 30 (8): 777–82. Chinese. DOI:10.3760/cma.j.issn.2095-4352.2018.08.013; https://www.surgonco.ru/jour/article/view/814

الاتاحة: https://www.surgonco.ru/jour/article/view/814
https://doi.org/10.24060/2076-3093-2023-13-2-165-170

المؤلفون: V. V. Protoshchak, I. A. Solov'ev, V. S. Chirskiy, M. V. Vasilchenko, L. M. Sinelnikov, M. V. Paronnikov, E. G. Karpushchenko, A. A. Erokhina, S. A. Alentiev, M. V. Lazutkin, В. В. Протощак, И. А. Соловьев, В. С. Чирский, М. В. Васильченко, Л. М. Синельников, М. В. Паронников, Е. Г. Карпущенко, А. А. Ерохина, С. А. Алентьев, М. В. Лазуткин

المصدر: Cancer Urology; Том 17, № 1 (2021); 178-184 ; Онкоурология; Том 17, № 1 (2021); 178-184 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: рак, carcinosarcoma, sarcomatoid, tumor, cancer, карциносаркома, саркоматоид, опухоль

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1312/1256; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1312/850; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1312/851; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1312/852; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1312/853; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1312/854; Humphrey P.A. Histological variants of prostatic carcinoma and their significance. Histopathology 2012;60(1):59—74. DOI:10.1111/j.1365-2559.2011.04039.x.; Somarelli J.A., Boss M.K., Epstein J.I. et al. Carcinosarcomas: tumors in transition? Histol Histopathol 2015;30(6):673-87. DOI:10.14670/HH-30.673.; Dundore P.A., Cheville J.C., Nascimento A.G. et al. Carcinosarcoma of the prostate. Report of 21 cases. Cancer 1995;76(6):1035-42. DOI:10.1002/1097-0142(19950915)76:63.0.co;2-8.; Hamlin W.B., Lund P.K. Carcinosarcoma of the prostate: a case report. J Urol 1967;97(3):518-22. DOI:10.1016/s0022-5347(17)63071-4.; Markowski M.C., Eisenberger M.A., Zahurak M. et al. Sarcomatoid carcinoma of the prostate: retrospective review of a case series from the Johns Hopkins Hospital. Urology 2015;86(3):539-43. DOI:10.1016/j.urology.2015.06.011.; Lauwers G.Y., Schevchuk M., Armenakas N., Reuter V.E. Carcinosarcoma of the prostate. Am J Surg Pathol 1993;17(4):342-9. DOI:10.1097/00000478-199304000-00004.; Протощак В.В., Андреев Е.А., Карпущенко Е.Г. и др. Рак предстательной железы и обоняние собак: возможности неинвазивной диагностики. Урология 2019;5:22-6. DOI:10.18565/urology.2019.5.22-26.; https://oncourology.abvpress.ru/oncur/article/view/1312

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1312
https://doi.org/10.17650/1726-9776-2021-17-1-178-184

المؤلفون: D. V. Vasilchenko, N. V. Krakhmal, S. V. Vtorushin, M. V. Zavyalova, Д. В. Васильченко, Н. В. Крахмаль, С. В. Вторушин, М. В. Завьялова

المصدر: Siberian journal of oncology; Том 19, № 3 (2020); 146-155 ; Сибирский онкологический журнал; Том 19, № 3 (2020); 146-155 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-3

مصطلحات موضوعية: факторы прогноза, FOXA1, ELF5, breast cancer, prognosis factors, рак молочной железы

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1498/757; Simon I., Barnett J., Hannett N., Harbison C.T., Rinaldi N.J., Volkert T.L., Wyrick J.J., Zeitlinger J., Gifford D.K., Jaakkola T.S., Young R.A. Serial regulation of transcriptional regulators in the yeast cell cycle. Cell. 2001 Sep 21; 106(6): 697–708. doi:10.1016/s0092-8674(01)00494-9.; Accili D., Arden K.C. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004 May 14; 117(4): 421–6. doi:10.1016/s0092-8674(04)00452-0.; Vaquerizas J.M., Kummerfeld S.K., Teichmann S.A., Luscombe N.M. A census of human transcription factors: function, expression and evolution. Nat Rev Genet. 2009 Apr; 10(4): 252–63. doi:10.1038/nrg2538.; Singh M., Ding Y., Zhang L.Y., Song D., Gong Y., Adams S., Ross D.S., Wang J.H., Grover S., Doval D.C., Shao C., He Z.L., Chang V., Chin W.W., Deng F.M., Singh B., Zhang D., Xu R.L., Lee P. Distinct breast cancer subtypes in women with early-onset disease across races. Am J Cancer Res. 2014; 4(4): 337–52.; Lambert S.A., Jolma A., Campitelli L.F., Das P.K., Yin Y., Albu M., Chen X., Taipale J., Hughes T.R., Weirauch M.T. The Human Transcription Factors. Cell. 2018 Feb 8; 172(4): 650–665. doi:10.1016/j.cell.2018.01.029.; Boyadjiev S.A., Jabs E.W. Online Mendelian Inheritance in Man (OMIM) as a knowledgebase for human developmental disorders. Clin Genet. 2000 Apr; 57(4): 253–66. doi:10.1034/j.1399-0004.2000.570403.x.; Furney S.J., Higgins D.G., Ouzounis C.A., López-Bigas N. Structural and functional properties of genes involved in human cancer. BMC Genomics. 2006 Jan 11; 7: 3. doi:10.1186/1471-2164-7-3.; Papavassiliou K.A., Papavassiliou A.G. Transcription factor drug targets. J. Cell Biochem. 2016 May; 117(12): 2693–2696. doi:10.1002/jcb.25605.; Hagenbuchner J., Ausserlechner M.J. Targeting transcription factors by small compounds Current strategies and future implications. Biochem Pharmacol. 2016 May; 107: 1–13. doi:10.1016/j.bcp.2015.12.006.; Liu H., Shi J., Wilkerson M.L., Lin F. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012 Jul; 138(1): 57–64. doi:10.1309/AJCP5UAFMSA9ZQBZ.; Braxton D.R., Cohen C., Siddiqui M.T. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens. Diagn Cytopathol. 2015 Aug; 43(4): 271–7. doi:10.1002/dc.23206.; Zheng R., Blobel G.A. GATA Transcription Factors and Cancer. Genes Cancer. 2010 Dec; 1(12): 1178–1188. doi:10.1177/1947601911404223.; Lentjes M.H.F.M., Niessen H.E.C., Akiyama Y., de Bruïne A.P., Melotte V., van Engeland M. The emerging role of GATA transcription factors in development and disease. Expert Rev Mol Med. 2016 Mar; 18: e3. doi:10.1017/erm.2016.2.; Miettinen M., McCue P.A., Sarlomo-Rikala M., Rys J., Czapiewski P., Wazny K., Langfort R., Waloszczyk P., Biernat W., Lasota J., Wang Z. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014 Jan; 38(1): 13–22. doi:10.1097/PAS.0b013e3182a0218f.; Sellheyer K., Krahl D. Expression pattern of GATA-3 in embryonic and fetal human skin suggests a role in epidermal and follicular morphogenesis. J Cutan Pathol. 2010 Mar; 37(3): 357–361. doi:10.1111/j.1600-0560.2009.01416.x.; Theodorou V., Stark R., Menon S., Carroll J.S. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res. 2013 Jan; 23(1): 12–22. doi:10.1101/gr.139469.112.; Gustin J.P., Miller J., Farag M., Rosen D.M., Thomas M., Scharpf R.B., Lauring J. GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers. Oncotarget. 2017 Oct 20; 8(61): 103415–427. doi:10.18632/oncotarget.21910.; Emmanuel N., Lofgren K.A., Peterson E.A., Meier D.R., Jung E.H., Kenny P.A. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Anticancer Res. 2018; 38(8): 4435–41. doi:10.21873/anticanres.12745.; Fang S.H., Chen Y., Weigel R.J. GATA-3 as a marker of hormone response in breast cancer. J Surg Res. 2009 Dec; 157(2): 290–5. doi:10.1016/j.jss.2008.07.015.; Izzo F., Mercogliano F., Venturutti L., Tkach M., Inurrigarro G., Schillaci R., Cerchietti L., Elizalde V.P., Proietti C. Progesterone receptor activation down regulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. Breast Cancer Res. 2014 Dec; 16: 491. doi:10.1186/s13058-014-0491-x.; Yan W., Cao Q.J., Arenas R.B., Bentley B., Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem. 2010 Apr; 285(18): 14042–51. doi:10.1074/jbc.M110.105262.; Si W., Huang W., Zheng Y., Yang Y., Liu X., Shan L., Zhou X., Wang Y., Su D., Gao J., Yan R., Han X., Li W., He L., Shi L., Xuan C., Liang J., Sun L., Wang Y., Shang Y. Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell. 2015 Jun; 27(6): 822–836. doi:10.1016/j.ccell.2015.04.011.; Yu W., Huang W., Yang Y., Qiu R., Zeng Y., Hou Y., Sun G., Shi H., Leng S., Feng D., Chen Y., Wang S., Teng X., Yu H., Wang Y. GATA3 recruits UTX for gene transcriptional activation to suppress metastasis of breast cancer. Cell Death Dis. 2019 Nov 4; 10(11): 832. doi:10.1038/s41419-019-2062-7.; Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61–70. doi:10.1038/nature11412.; Pereira B., Chin S.F., Rueda O.M., Vollan H.K., Provenzano E., Bardwell H.A., Pugh M., Jones L., Russell R., Sammut S.J., Tsui D.W., Liu B., Dawson S.J., Abraham J., Northen H., Peden J.F., Mukherjee A., Turashvili G., Green A.R., McKinney S., Oloumi A., Shah S., Rosenfeld N., Murphy L., Bentley D.R., Ellis I.O., Purushotham A., Pinder S.E., BørresenDale A.L., Earl H.M., Pharoah P.D., Ross M.T., Aparicio S., Caldas C. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016 May 10; 7: 11479. doi:10.1038/ncomms11479.; Mair B., Konopka T., Kerzendorfer C., Sleiman K., Salic S., Serra V., Muellner M.K., Theodorou V., Nijman S.M. Gain- and Loss-ofFunction Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genet. 2016 Sep 2; 12(9): e1006279. doi:10.1371/journal.pgen.1006279.; Takaku M., Grimm S.A., Roberts J.D., Chrysovergis K., Bennett B.D., Myers P., Perera L., Tucker C.J., Perou C.M., Wade P.A. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun. 2018 Mar 13; 9(1): 1059. doi:10.1038/s41467-018-03478-4.; Gonzalez R.S., Wang J., Kraus T., Sullivan H., Adams A.L., Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013 Jun; 44(6): 1065–70. doi:10.1016/j.humpath.2012.09.010.; Mehra R., Varambally S., Ding L., Shen R., Sabel M.S., Ghosh D., Chinnaiyan A.M., Kleer C.G. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 2005 Dec 15; 65(24): 11259–64. doi:10.1158/0008-5472.CAN-05-2495.; Viedma-Rodríguez R., Baiza-Gutman L., Salamanca-Gómez F., Diaz-Zaragoza M., Martínez-Hernández G., Ruiz Esparza-Garrido R., Velázquez-Flores M.A., Arenas-Aranda D. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep. 2014 Jul; 32(1): 3–15. doi:10.3892/or.2014.3190.; Jiang Y.Z., Yu K.D., Zuo W.J., Peng W.T., Shao Z.M. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer. 2014 May 1; 120(9): 1329–37. doi:10.1002/cncr.28566.; Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., Wallis J.W., Van Tine B.A., Hoog J., Goiffon R.J., Goldstein T.C., Ng S., Lin L., Crowder R., Snider J., Ballman K., Weber J., Chen K., Koboldt D.C., Kandoth C., Schierding W.S., McMichael J.F., Miller C.A., Lu C., Harris C.C., McLellan M.D., Wendl M.C., DeSchryver K., Allred D.C., Esserman L., Unzeitig G., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Leitch M., Hunt K., Olson J., Tao Y., Maher C.A., Fulton L.L., Fulton R.S., Harrison M., Oberkfell B., Du F., Demeter R., Vickery T.L., Elhammali A., Piwnica-Worms H., McDonald S., Watson M., Dooling D.J., Ota D., Chang L.W., Bose R., Ley T.J., Piwnica-Worms D., Stuart J.M., Wilson R.K., Mardis E.R. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012 Jun 10; 486(7403): 353–60. doi:10.1038/nature11143.; Sangoi A.R., Shrestha B., Yang G., Mego O., Beck A.H. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. Appl Immunohistochem Mol Morphol. 2016 Apr; 24(4): 229–37. doi:10.1097/PAI.0000000000000186.; Laurent E., Begueret H., Bonhomme B., Veillon R., Thumerel M., Velasco V., Brouste V., Hoppe S., Fournier M., Grellety T., MacGrogan G. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. Am J Surg Pathol. 2019 Mar; 43(3): 293–302. doi:10.1097/PAS.0000000000001216.; Hannenhalli S., Kaestner K.H. The evolution of Fox genes and their role in development and disease. Nat Rev Genet. 2009 Apr; 10(4): 233–40. doi:10.1038/nrg2523.; Bernardo G.M., Keri R.A. FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep. 2012; 32(2): 113–30. doi:10.1042/BSR20110046.; Robinson J.L., Holmes K.A., Carroll J.S. FOXA1 mutations in hormone-dependent cancers. Front Oncol. 2013; 3: 20. doi:10.3389/fonc.2013.00020.; Zhang G., Zhao Y., Liu Y., Kao L.P., Wang X., Skerry B., Li Z. FOXA1 defines cancer cell specificity. Sci Adv. 2016 Mar; 2(3): e1501473. doi:10.1126/sciadv.1501473.; Carroll J.S. Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur. J. Endocrinol. 2016 Jul; 75(1): 41–9. doi:10.1530/EJE-16-0124.; Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet. 2011 Jan; 43(1): 27–33. doi:10.1038/ng.730.; Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., Nickerson E., Chae S.S., Boysen G., Auclair D., Onofrio R.C., Park K., Kitabayashi N., MacDonald T.Y., Sheikh K., Vuong T., Guiducci C., Cibulskis K., Sivachenko A., Carter S.L., Saksena G., Voet D., Hussain W.M., Ramos A.H., Winckler W., Redman M.C., Ardlie K., Tewari A.K., Mosquera J.M., Rupp N., Wild P.J., Moch H., Morrissey C., Nelson P.S., Kantoff P., Gabriel S.B., Golub T.R., Meyerson M., Lander E.S., Getz G., Rubin M., Garraway L.A. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May; 44(6): 685–9. doi:10.1038/ng.2279.; Yang Y.A., Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015 Jun; 2(2): 144–151. doi:10.1016/j.gendis.2015.01.003.; Nakshatri H., Badve S. FOXA1 in breast cancer. Expert Rev Mol Med. 2009 Mar; 11:e8. doi:10.1017/S1462399409001008.; Yamaguchi N., Ito E., Azuma S., Honma R., Yanagisawa Y., Nishikawa A., Kawamura M., Imai J., Tatsuta K., Inoue J., Semba K., Watanabe S. FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem Biophys Res Commun. 2008 Jan; 365(4): 711–7. doi:10.1016/j.bbrc.2007.11.064.; Shigekawa T., Ijichi N., Ikeda K., Horie-Inoue K., Shimizu C., Saji S., Aogi K., Tsuda H., Osaki A., Saeki T., Inoue S. FOXP1, an estrogeninducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer. 2011 Oct; 2(5): 286–97. doi:10.1007/s12672- 011-0082-6.; Bernardo G.M., Bebek G., Ginther C.L., Sizemore S.T., Lozada K.L., Miedler J.D., Anderson L.A., Godwin A.K., Abdul-Karim F.W., Slamon D.J., Keri R.A. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. 2013 Jan; 32(5): 554–63. doi:10.1038/onc.2012.62.; Rangel N., Fortunati N., Osella-Abate S., Annaratone L., Isella C., Catalano M.G., Rinella L., Metovic J., Boldorini R., Balmativola D., Ferrando P., Marano F., Cassoni P., Sapino A., Castellano I. FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients. BMC Cancer. 2018; 18(1): 703. doi:10.1186/s12885-018-4624-y.; Bozovic-Spasojevic I., Zardavas D., Brohee S., Ameye L., Fumagalli D., Ades F., de Azambuja E., Bareche Y., Piccart M., Paesmans M., Sotiriou S. The prognostic role of androgen receptor in patients with earlystage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res. 2017 Jun; 23(11): 2702–2712. doi:10.1158/1078-0432.CCR-16-0979.; Hisamatsu Y., Tokunaga E., Yamashita N., Akiyoshi S., Okada S., Nakashima Y., Taketani K., Aishima S., Oda Y., Morita M., Maehara Y. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. Breast cancer. 2015; 22(5): 520–8. doi:10.1007/s12282-013-0515-x.; Horimoto Y., Arakawa A., Harada-Shoji N., Sonoue H., Yoshida Y., Himuro T., Igari F., Tokuda E., Mamat O., Tanabe M., Hino O., Saito M. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer. 2015 Jan; 112(2): 345–51. doi:10.1038/bjc.2014.595.; De Lara S., Nyqvist J., Werner Rönnerman E., Helou K., Kenne Sarenmalm E., Einbeigi Z., Karlsson P., Parris T.Z., Kovács A. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014). BMC Cancer. 2019 Feb; 19(1): 187. doi:10.1186/s12885-019-5373-2.; Jing X., Liang H., Hao C., Hongxia L., Cui X. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer. Aging (Albany NY). 2019 Sep 28; 11(18): 7442–7456. doi:10.18632/aging.102250.; Yamaguchi N., Nakayama Y., Yamaguchi N. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J Biol Chem. 2017 May; 292(20): 8136–8148. doi:10.1074/jbc.M116.763276.; Fu X., Jeselsohn R., Pereira R., Hollingsworth E.F., Creighton C.J., Li F., Shea M., Nardone A., De Angelis C., Heiser L.M., Anur P., Wang N., Grasso C.S., Spellman P.T., Griffith O.L., Tsimelzon A., Gutierrez C., Huang S., Edwards D.P., Trivedi M.V., Rimawi M.F., Lopez-Terrada D., Hilsenbeck S.G., Gray J.W., Brown M., Osborne C.K., Schiff R. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci USA. 2016 Oct; 113(43): 6600–6609. doi:10.1073/pnas.1612835113.; Robinson J.L., Hickey T.E., Warren A.Y., Vowler S.L., Carroll T., Lamb A.D., Papoutsoglou N., Neal D.E., Tilley W.D., Carroll J.S. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene. 2014; 33(50): 5666–74. doi:10.1038/onc.2013.508.; Robinson D.R., Wu Y.M., Vats P., Su F., Lonigro R.J., Cao X., Kalyana-Sundaram S., Wang R., Ning Y., Hodges L., Gursky A., Siddiqui J., Tomlins S.A., Roychowdhury S., Pienta K.J., Kim S.Y., Roberts J.S., Rae J.M., Van Poznak C.H., Hayes D.F., Chugh R., Kunju L.P., Talpaz M., Schott A.F., Chinnaiyan A.M. Activating ESR1 mutations in hormoneresistant metastatic breast cancer. Nat.Genet. 2013 Dec; 45(12): 1446–51. doi:10.1038/ng.2823.; Jeselsohn R., De Angelis C., Brown M., Schiff R. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Curr Oncol Rep. 2017 May; 19(5): 35. doi:10.1007/s11912-017-0591-8.; Van Poznak C., Somerfield M.R., Bast R.C., Cristofanilli M., Goetz M.P., Gonzalez-Angulo A.M., Hicks D.G., Hill E.G., Liu M.C., Lucas W., Mayer I.A., Mennel R.G., Symmans W.F., Hayes D.F., Harris L.N. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women with Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug; 33(24): 2695–704. doi:10.1200/JCO.2015.61.1459.; Schrijver W., Schuurman K., van Rossum A., Droog M., Jeronimo C., Salta S., Henrique R., Wesseling J., Moelans C., Linn S.C., van den Heuvel M., van Diest P., Zwart W. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Mol Oncol. 2018 Nov; 12(11): 1884–94. doi:10.1002/1878-0261.12353.; Wang W., Yi M., Chen S., Li J., Li G., Yang J., Zheng P., Zhang H., Xiong W., McCarthy J.B., Li G., Li X., Xiang B. Significance of the NOR1- FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells. Oncotarget. 2016; 7(13): 16745–59. doi:10.18632/oncotarget.7778.; Anzai E., Hirata K., Shibazaki M., Yamada C., Morii M., Honda T., Yamaguchi N., Yamaguchi N. FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells. Biol Pharm Bull. 2017; 40(9): 1483–1489. doi:10.1248/bpb.b17-00307.; Choi Y.S., Chakrabarti R., Escamilla-Hernandez R., Sinha S. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol. 2009 May; 329(2): 227–41. doi:10.1016/j.ydbio.2009.02.032.; Kalyuga M., Gallego-Ortega D., Lee H.J., Roden D.L., Cowley M.J., Caldon C.E., Stone A., Allerdice S.L., Valdes-Mora F., Launchbury R., Statham A.L., Armstrong N., Alles M.C., Young A., Egger A., Au W., Piggin C.L., Evans C.J., Ledger A., Brummer T., Oakes S.R., Kaplan W., Gee J.M., Nicholson R.I., Sutherland R.L., Swarbrick A., Naylor M.J., Clark S.J., Carroll J.S., Ormandy C.J. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol. 2012; 10(12): e1001461. doi:10.1371/journal.pbio.1001461.; Oakes S.R., Naylor M.J., Asselin-Labat M.L., Blazek K.D., Gardiner-Garden M., Hilton H.N., Kazlauskas M., Pritchard M.A., Chodosh L.A., Pfeffer P.L., Lindeman G.J., Visvader J.E., Ormandy C.J. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev. 2008 Mar; 22(5): 581–6. doi:10.1101/gad.1614608.; Tanos T., Sflomos G., Echeverria P.C., Ayyanan A., Gutierrez M., Delaloye J.F., Raffoul W., Fiche M., Dougall W., Schneider P., YalcinOzuysal O., Brisken C. Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med. 2013 Apr; 5(182): 182ra55. doi:10.1126/scitranslmed.3005654.; Harris J., Stanford P.M., Sutherland K., Oakes S.R., Naylor M.J., Robertson F.G., Blazek K.D., Kazlauskas M., Hilton H.N., Wittlin S., Alexander W.S., Lindeman G.J., Visvader J.E., Ormandy C.J. Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol. 2006 May; 20(5): 1177–87. doi:10.1210/me.2005-0473.; Battula V.L., Evans K.W., Hollier B.G., Shi Y., Marini F.C., Ayyanan A., Wang R.Y., Brisken C., Guerra R., Andreeff M., Mani S.A. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010; 28(8): 1435–45. doi:10.1002/stem.467.; Chakrabarti R., Hwang J., Andres Blanco M., Wei Y., Lukačišin M., Romano R.A., Smalley K., Liu S., Yang Q., Ibrahim T., Mercatali L., Amadori D., Haffty B.G., Sinha S., Kang Y. Elf5 inhibits the epithelialmesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012; 14(11): 1212–22. doi:10.1038/ncb2607.; Gallego-Ortega D., Ledger A., Roden D.L., Law A.M., Magenau A., Kikhtyak Z., Cho C., Allerdice S.L., Lee H.J., Valdes-Mora F., Herrmann D., Salomon R., Young A.I., Lee B.Y., Sergio C.M., Kaplan W., Piggin C., Conway J.R., Rabinovich B., Millar E.K., Oakes S.R., Chtanova T., Swarbrick A., Naylor M.J., O'Toole S., Green A.R., Timpson P., Gee J.M., Ellis I.O., Clark S.J., Ormandy C.J. ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ MyeloidDerived Suppressor Cells. PLoS Biol. 2015 Dec; 13(12): e1002330. doi:10.1371/journal.pbio.1002330.; Fitzgerald L.M., Browne E.P., Christie K.D., Punska E.C., Simmons L.O., Williams K.E., Pentecost B.T., Jawale R., Otis C.N., Arcaro K.F. ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors. Cancer Cell Int. 2016 Feb; 16: 8. doi:10.1186/s12935-016-0282-9.; Omata F., McNamara K.M., Suzuki K., Abe E., Hirakawa H., Ishida T., Ohuchi N.,•Sasano H. Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients. Breast Cancer. 2018. Jul; 25(4): 489–496. doi:10.1007/s12282-018-0842-z.; Yao B., Zhao J., Li Y., Li H., Hu Z., Pan P., Zhang Y., Du E., Liu R., Xu Y. Elf5 inhibits TGF-β-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation. Prostate. 2015; 75(8): 872–82. doi:10.1002/pros.22970.; Xie B.X., Zhang H., Wang J., Pang B., Wu R.Q., Qian X.L., Yu L., Li S.H., Shi Q.G., Huang C.F., Zhou J.G. Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl. 2011; 32(2): 170–82. doi:10.2164/jandrol.109.008748.; Wu B., Cao X., Liang X., Zhang X., Zhang W., Sun G., Wang D. Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer. PLoS One. 2015; 10(1): e0117510. doi:10.1371/journal.pone.0117510.; Lapinskas E.J., Svobodova S., Davis I.D., Cebon J., Hertzog P.J., Pritchard M.A. The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney. Twin Res Hum Genet. 2011; 14(4): 316–22. doi:10.1375/twin.14.4.316.; Risinger J.I., Maxwell G.L., Chandramouli G.V., Jazaeri A., Aprelikova O., Patterson T., Berchuck A., Barrett J.C. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003 Jan; 63(1): 6–11.; https://www.siboncoj.ru/jour/article/view/1498

الاتاحة: https://www.siboncoj.ru/jour/article/view/1498
https://doi.org/10.21294/1814-4861-2020-19-3-146-155

المؤلفون: S. V. Vtorushin, D. V. Vasilchenko, К. Y. Khristenko, N. V. Krakhmal, I. V. Stepanov, М. V. Zavyalova, E. M. Slonimskaya, S. V. Patalyak, С. В. Вторушин, Д. В. Васильченко, К. Ю. Христенко, Н. В. Крахмаль, И. В. Степанов, М. В. Завьялова, Е. М. Слонимская, С. В. Паталяк

المصدر: Siberian journal of oncology; Том 16, № 5 (2017); 42-47 ; Сибирский онкологический журнал; Том 16, № 5 (2017); 42-47 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-16-5

مصطلحات موضوعية: лекарственная устойчивость, transcription factor GATA3, lymph node metastasis, prognosis, drug resistance, транскрипционный фактор GATA3, лимфогенное метастазирование, прогноз

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/612/474; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) М., 2017. 250.; Cimino-Mathews A., Subhawong A.P., Illei P.B., Sharma R., Halushka M.K., Vang R., Fetting J.H., Park B.H., Argani P. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Hum Pathol. 2013 Jul; 44 (7): 1341–9. doi:10.1016/j.humpath.2012.11.003.; Byrne D.J., Deb S., Takano E.A., Fox S.B. GATA3 expression in triple-negative breast cancers. Histopathology. 2017 Jul; 71 (1): 63–71. doi:10.1111/his.13187.; Deftereos G., Sanguino Ramirez A.M., Silverman J.F., Krishnamurti U. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Am J Surg Pathol. 2015 Sep; 39 (9): 1282–9. doi:10.1097/ PAS.0000000000000505.; Gonzalez R.S., Wang J., Kraus T., Sullivan H., Adams A.L., Cohen C. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol. 2013 Jun; 44 (6): 1065–70. doi:10.1016/j.humpath.2012.09.010.; Yoon N.K., Maresh E.L., Shen D., Elshimali Y., Apple S., Horvath S., Mah V., Bose S., Chia D., Chang H.R., Goodglick L. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol. 2010 Dec; 41 (12): 1794–801. doi:10.1016/j.humpath.2010.06.010.; Mehra R., Varambally S., Ding L., Shen R., Sabel M.S., Ghosh D., Chinnaiyan A.M., Kleer C.G. Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. Cancer Res. 2005 Dec 15; 65 (24): 11259–64.; Shahi P., Wang C.Y., Chou J., Hagerling C., Gonzalez Velozo H., Ruderisch A., Yu Y., Lai M.D., Werb Z. GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. Oncogene. 2017 Oct 5; 36 (40): 5567–75. doi:10.1038/ onc.2017.165.; Tkocz D., Crawford N.T., Buckley N.E., Berry F.B., Kennedy R.D., Gorski J.J., Harkin D.P., Mullan P.B. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene. 2012 Aug 9; 31 (32): 3667–78. doi:10.1038/onc.2011.531.; Cohen H., Ben-Hamo R., Gidoni M., Yitzhaki I., Kozol R., Zilberberg A., Efroni S. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. Breast Cancer Res. 2014 Nov 20; 16 (6): 464. doi:10.1186/s13058-014-0464-0.; Hoch R.V., Thompson D.A., Baker R.J., Weigel R.J. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer. 1999 Apr 20; 84 (2): 122–8.; https://www.siboncoj.ru/jour/article/view/612

الاتاحة: https://www.siboncoj.ru/jour/article/view/612
https://doi.org/10.21294/1814-4861-2017-16-5-42-47

المؤلفون: Andrey V. Vasilchenko, Albert M. Gareev, А. В. Васильченко, А. М. Гареев

المصدر: Creative surgery and oncology; Том 7, № 3 (2017); 72-78 ; Креативная хирургия и онкология; Том 7, № 3 (2017); 72-78 ; 2076-3093 ; 2307-0501 ; 10.24060/2076-3093-2017-7-3

مصطلحات موضوعية: болезни имитация, self-mutilation, prisoners, patient simulation, членовредительство, заключенные

وصف الملف: application/pdf

Relation: https://www.surgonco.ru/jour/article/view/247/245; Соломенцев ВВ. Оценка мнения осужденных о проблеме умышленного причинения вреда своему здоровью. Journal of Siberian Medical Sciences. 2014;(1):14. [Solomentsev VV. Assessment of convicts’ opinion concerning the problem of deliberate bodily self-damage. Journal of Siberian Medical Sciences. 2014;(1):14 (in Russ.)].; Шабанов ВБ, Кашинский МЮ. Организационно-правовые проблемы противодействия суицидальным и несуицидальным аутодеструктивным проявлениям осужденных в местах лишения свободы. Вестник Воронежского института МВД России. 2012;(3):17-24. [Shabanov VB, Kashinskiy MYu. Organizational and legal problems of counteraction to suicidal and non-suicidal self-destructive indications of condemned in confinement institutions. The bulletin of Voronezh Institute of the Ministry of Internal Affairs of Russia. 2012;(3):17-24 (in Russ.)].; Васильченко АВ, Гареев АМ. Вопросы судебно-медицинской диагностики умышленного причинения вреда своему здоровью в местах лишения свободы. Актуальные проблемы государства и общества в области обеспечения прав и свобод человека и гражданина. 2016;(19-4):79-82. [Vasilchenko AV, Gareev AM. Issues of forensic diagnostics intentionally caused harm to health in the places of detention. Aktualnye Problemy Gosudarstva i Obshchestva v Oblasti Obespecheniya Prav i Svobod Cheloveka i Grazhdanina. 2016;(19-4):79-82 (in Russ.)].; Золотухин КН, Лешкова ВЕ, Галеев ФС. Антибиотикорезистентность у пациентов с абдоминальным сепсисом. особенности формуляра антибактериальных средств. Клиническая микробиология и антимикробная химиотерапия. 2001;3(1):16. [Zolotukhin KN, Leshkova VE, Galeev FS. Antibiotic resistance in patients with abdominal sepsis. features of the form of antibacterial agents. Klinicheskaya mikrobiologiya I antimikrobnaya khimioterapiya. 2001;3(1):16 )in Russ.)].; Золотухин КН, Поляков ИВ, Самородов АВ. Мониторинг энергозатрат у пациентов с печеночной недостаточностью после абдоминальных оперативных вмешательств в условиях ОРИТ. Тольяттинский Медицинский Консилиум. 2013;(1-2):15-18. [Zolotukhin KN, Polyakov IV, Samorodov AV. Energy consumption monitoring in patients with liver failure after abdominal surgery in the ICU. Togliatti Medical Consultation. 2013;(1-2):15-18 (in Russ.)].; Ураков АЛ, Самородов АВ, Камилов ФХ, Мустафин ИГ, Халиуллин ФА. Особенности экспрессии Р-селектина и агрегации тромбоцитов под действием лекарственных препаратов. Фармация. 2017; 66(3):43-46. [Urakov AL, Samorodov AV, Kamilov FKh, Mustafin IG, Khaliullin FA. P-selectin expression of and platelet aggregation under the action of drugs. Pharmacy. 2017; 66(3):43-46 (in Russ.)].; Ураков АЛ, Самородов АВ, Камилов ФХ, Халиуллин ФА. Полирегионарная агрегатометрия крови пациентов с острым тромбозом, как потенциальная модель доклинических исследований новых корректоров системы гемостаза ex vivo. Регионарное кровообращение и микроциркуляция. 2017;16(1):65-71. [Urakov AL, Samorodov AV, Kamilov FKh, Khaliullin FA. Polyregional aggregatometry of blood in patients with acute thrombosis as a potential model for preclicinal studies of new correctors of hemostasis system ex vivo. Regional Haemodynamics and Microcirculation. 2017;16(1):65-71 (in Russ.)].; Золотухин КН, Поляков ИВ, Самородов АВ. Сравнительный анализ мониторинга центральной гемодинамики монитором МПР 6-03 «Тритон» и «Picco Plus». Тольяттинский Медицинский Консилиум. 2012;(3-4):19-23. [Zolotukhin KN, Polyakov IV, Samorodov AV. Comparative analysis of circulatory dynamics monitoring with heartbeat monitor «Triton» vs. «PiccoPlus». Togliatti Medical Consultation. 2012;3-4:19-23 (in Russ.)].; Косарев ВВ, Бабанов СА. Фармакоэпидемиологические и фармакоэкономические исследования в современной медицине. Семейная медицина. 2012;(6):90-94. [Kosarev VV, Babanov SA. Pharmacoepidemiological and pharmacoeconomic studies in modern medicine. Family Medicine. 2012;(6):90-94 (in Russ.)].; Global initiative for chronic obstructive lung disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. [Internet] Available from: http:// www.goldcopd.org.; Соломенцев В.В. Умышленное причинение вреда своему здоровью осужденными (междисциплинарный аспект подготовки врачей и юристов высшей школы) // Современные проблемы науки и образования. 2014;(3):434. [Solomentsev VV. Intentional infliction of harm to their health (the interdisciplinary aspect of the training of doctors and lawyers of the higher school. Modern problems of science and education. 2014;(3):434 (in Russ.)].; Принципы медицинской этики, относящиеся к роли работников здравоохранения, в особенности врачей, в защите заключенных или задержанных лиц от пыток и других жестоких, бесчеловечных или унижающих достоинство видов обращения и наказания [Электронный ресурс]. Нью-Йорк; Организация Объединенных Наций, 1982. Доступно по: http://www.un.org/ru/documents/decl_conv/conventions/medical_ethics_principles.shtml. Ссылка активна на 17.11.2014.; Dooris M. Holistic and sustainable health improvement: the contribution of the settingsbased approach to health promotion. Perspectives in Public Health. 2009;129(1):29-36. DOI:10.1177/1757913908098881.; Gatherer A, Fraser A, Hayton P, Moller L. Public health leadership, social justice and the socially marginalised. Public Health. 2010;124(11):617-19. DOI:10.1016/j.puhe.2010.08.015.; https://www.surgonco.ru/jour/article/view/247

الاتاحة: https://www.surgonco.ru/jour/article/view/247
https://doi.org/10.24060/2076-3093-2017-7-3-72-78

المؤلفون: Г. В. Васильченко

المصدر: Фінансово-кредитна діяльність: проблеми теорії та практики, Vol 2, Iss 11 (2014)

مصطلحات موضوعية: aутсорсинг, управління, суб’єкт господарювання, реальний сектор економіки, фінансовий сектор економіки, Economics as a science, HB71-74, Business, HF5001-6182

Relation: https://fkd.net.ua/index.php/fkd/article/view/2664; https://doaj.org/toc/2306-4994; https://doaj.org/toc/2310-8770; https://doaj.org/article/fe97d91c4c3f46d9bf9fa5f2ff193030

الاتاحة: https://doaj.org/article/fe97d91c4c3f46d9bf9fa5f2ff193030